Virax Biolabs Group Limited announced building on the commercial launch of ImmuneSelect portfolio, the company is expanding global distribution infrastructure. In 2024, the company reached agreements with regional distributors Europa Biosite and Tebubio to distribute ImmuneSelect products across the European Union, as well as the UK, Norway, and Switzerland; increasing access for researchers and pharmaceutical entities in that region. In addition, the company have signed country specific distribution agreements for ImmuneSelect in Spain and Portugal with Abyntek Biopharma, and in Italy with DBA Italia.
To expand access further, it aim to secure U.S. distribution partners by First Quarter of 2025. These developments have been supplemented by the continued expansion of ViraxClear distribution channels. The company entered into a new agreement to supply Mpox Virus Real-Time PCR Detection Kits to 13 European countries and the Middle East.
The company also expanded current agreement with Cosmos Health to extend the distribution of the Mpox Virus Real-Time PCR Detection Kits to countries in the Gulf Cooperation Council (GCC) and India. In addition, ViraxClear maintains the capability to distribute H5N1 testing kits, commonly known as Avian Flu tests, and can ship them as needed. In 2025, key priorities include: Advancing ViraxImmune UK and U.S. Clinical Validation Studies: It will be leveraging insights gained from ongoing data and collaborations to fine-tune offerings for broad-scale deployment.
The company expects to present key data at major international scientific conferences. U.S. regulatory Progress: It aim to initiate formal interactions with regulatory authorities to define the approval pathway for the ViraxImmune IVD platform. This step is critical to transitioning innovative assays into clinical use.
Expansion of ImmuneSelect Distribution Channels: Building on recent agreements, the company will focus on growing presence in additional markets, with particular emphasis on the Americas, and into U.S.-based markets. Initiation of Protective Immunity IVD clinical performance study (Lyme Disease and Pre & Post Transplant Infection).
